ANVS

Annovis Bio, Inc.

6.75 USD
+0.10 (+1.50%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Annovis Bio, Inc. stock is down -7.28% since 30 days ago. The next earnings date is Aug 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 20 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 10 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 May 19:27 19 Jul, 2024 5.00 PUT 291 3979
17 May 19:02 17 May, 2024 10.00 PUT 201 1911
17 May 19:05 17 May, 2024 10.00 PUT 200 1911
21 May 16:38 19 Jul, 2024 5.00 PUT 158 4502
21 May 16:38 19 Jul, 2024 5.00 PUT 430 4502
21 May 16:38 19 Jul, 2024 5.00 PUT 182 4502
28 May 14:14 19 Jul, 2024 5.00 PUT 250 5326
28 May 14:23 19 Jul, 2024 5.00 PUT 235 5326
28 May 15:00 17 Jan, 2025 7.50 PUT 54 111
28 May 17:03 19 Jul, 2024 2.50 PUT 754 14604

About Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for Alzheimer's disease.

  • HC Wainwright & Co.
    Mon May 13, 07:48
    buy
    confirm
  • Canaccord Genuity
    Tue Apr 30, 08:01
    buy
    confirm
  • HC Wainwright & Co.
    Tue Apr 30, 06:23
    buy
    confirm